Cutaneous adverse reaction (includes severe cutaneous adverse drug reaction (SCAR))

• (2021): Torres-Navarro I+, J Eur Acad Dermatol Venereol 35(3), 607-614 (severe) [REVIEW] (with a MEK inhibitor)

Cutaneous toxicity / skin toxicity

• (2015): Macdonald JB+, J Am Acad Dermatol 72(2), 221 [REVIEW]

DRESS syndrome (Drug-induced hypersensitivity syndrome)

• (2021): Rana J+, JAAD Case Rep 13, 147-151 (5 cases) (associated with prior immune checkpoint inhibitor therapy)

Exanthems

• (2014): Choi JN, Semin Cutan Med Surg 33(1), 40 [REVIEW]
• (2014): Reyes-Habito CM+, J Am Acad Dermatol 71(2), 217

Hand–foot syndrome (palmar–plantar erythrodysesthesia)

• (2021): Liu X+, Front Oncol Apr (e-Collection) 83%

Hyperkeratosis

• (2017): Vigarios E+, Support Care Cancer 25(5), 1713

Keratoacanthoma (Grzybowski syndrome)

• (2021): Liu X+, Front Oncol Apr (e-Collection) (2 cases)

Neutrophilic eccrine hidradenitis

• (2017): Herms F+, Br J Dermatol 176(6), 1645-1648 (2 cases)

Photosensitivity

• (2021): Liu X+, Front Oncol Apr (e-Collection) 25% (3 cases)
• (2014): Choi JN, Semin Cutan Med Surg 33(1), 40-8 [REVIEW]

Pruritus (itching)

• (2021): Liu X+, Front Oncol Apr (e-Collection) 50%

Rash

• (2021): Liu X+, Front Oncol Apr (e-Collection) 83% (grade 3–4 / 2 cases)

Alopecia / hair loss

• (2021): Liu X+, Front Oncol Apr (e-Collection) 58%

Cardiotoxicity

• (2021): Arangalage D+, Cancer Treat Rev Aug, Online ahead of print [REVIEW]

Gastrointestinal adverse reaction

• (2021): Liu X+, Front Oncol Apr (e-Collection) 25%

Arthralgia

• (2021): Liu X+, Front Oncol Apr (e-Collection) 58%

Myalgia/Myositis/Myopathy/Myotoxicity

• (2021): Liu X+, Front Oncol Apr (e-Collection) 42%

Ocular adverse effect

• (2021): Mettler C+, Ophthalmology May, Online ahead of print [REVIEW]

Uveitis / anterior uveitis / posterior uveitis / panuveitis

• (2023): Thibault T+, Ophthalmology Oct, Online ahead of print (association)

Adverse effects / adverse reactions

• (2021): Liu X+, Front Oncol Apr (e-Collection) 100% (grade 3–4 / 4 cases (33%))
• (2021): Ponrartana S+, Pediatr Radiol 51(5), 736-747 [REVIEW]
• (2017): Below J+, Hautarzt (German) 68(1), 12 [REVIEW] (cutaneous)
• (2017): Bottlaender L+, Melanoma Res 27(1), 68 (osteosclerotic lesions)